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Abstract 
 Cancer is a leading cause of death worldwide, resulting in an estimated 1.6 million mortalities 
and 600,000 new cases in the US alone in 2015. Gene fusions, hybrid genes formed from two originally 
separated genes, are known drivers of cancer. However, gene fusions have also been found in healthy 
cells due to routine errors in replication. This project aims to understand the role of gene fusion in 
cancer. Specifically, we seek to achieve two goals. First, we would like to develop a computational 
method that predicts if a gene fusion event is associated with the cancer or healthy sample. Second,  we 
would like to use this information to determine and characterize molecular mechanisms behind the 
gene fusion events. Recent studies have attempted to address these problems, but without explicit 
consideration of the fact that there are overlapping fusion events in both cancer and healthy cells. Here, 
we address this problem using FUsion Enriched Learning of CANcer Mutations (FUELCAN), a semi-
supervised model, which classifies all overlapping fusion events as unlabeled to start. The model is 
trained using the known cancer and healthy samples and tested using the unlabeled dataset. Unlabeled 
data is classified as associated with healthy or cancer samples and the top 20 data points are put back 
into the training set. The process continues until all have been appropriately classified. Three datasets 
were analyzed from Acute Lymphoblastic Leukemia (ALL), breast cancer and colorectal cancer. We 
obtained similar results for both supervised and semi-supervised classification. To improve our model, 
we assessed the functional landscape of gene fusion events and observed that the pathway neighbors of 
both gene fusion partners are differentially expressed in each cancer dataset. The significant neighbors 
are also shown to have direct connections to cancer pathways and functions, indicating that these gene 
fusions are important for cancer development. Future directions include applying the acquired 
transcriptomic knowledge to our machine learning algorithm, counting transcription factors and kinases 
within the gene fusion events and their neighbors and assessing the differences between upstream and 
downstream effects within the pathway neighbors. 
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1. INTRODUCTION 
 In the past decade, the discovery and optimization of next-generation sequencing (NGS) 
technologies has allowed us to more deeply study the intricacies of the genome. While the full potential 
of NGS technologies has not yet been realized and some improvements are necessary, we are able to 
look at our genome in a higher resolution and find both small and large chromosomal aberrations that 
may contribute to complex diseases such as cancer, diabetes and neurological disorders. A few of these 
mutations, such as copy number variants and single nucleotide polymorphisms, have been studied in 
great detail (Cui, 2015) and are known to be prospective targets for the treatment and cures of these 
diseases. Another type of these mutations, which has proven to have a direct connection with many 
types of cancer, are gene fusions. Gene fusions occur when two genes from distinctly separate parts of 
the genome, merge together to form one unit (Mertens, 2015). This event can result in a functional or 
non-functional gene product, depending on factors including frame shift, intact domain architecture and 
location of the nearest promoter (Latysheva, 2016).  
1.1 CHROMOSOMAL ABNORMALITIES IN CANCER: A BRIEF HISTORY 
 The first known gene fusion event discovered was the Philadelphia chromosome in chronic 
myeloid leukemia (CML). This event resulted in the translocation of the gene ABL from chromosome 
9 to chromosome 22 and merges with the BCR gene. The product is a shortened chromosome 22 and a 
lengthened chromosome 9 (Nowell and Hungerford, 1960). The Philadelphia Chromosome is known 
first mutation shown to drive cancer and this specific mutation has also been seen in other 
hematological cancers such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia 
(AML) (Rowley, 1973). Since the discovery of the Philadelphia chromosome, there have been many 
more fusion events found in both hematological and solid cancers (Mertens, 2015; Mitelman, 2007). 
While numerous gene fusions events have been discovered to drive cancer, many of gene fusions have 
been also found in healthy cells as a result of routine errors in DNA replication (Janz, 2003). These 
gene fusions are assumed benign but have not been studied in depth. 
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 The purpose of this project is two-fold. Firstly, in collaboration with Oleksandr Narykov, we 
seek to automate the classification task of which of gene fusion events are derived identify those 
derived from healthy samples, which may indicate that they are benign, and those derived from cancer 
samples, which may indicate malignancy. We will also then take a systems approach to determine the 
pathway landscape of these events, and attempt to predict regulatory mechanisms for driver gene fusion 
events in three different cancer types: ALL, breast cancer and colorectal cancer. 
1.2 MOLECULAR CHARACTERISTICS AND MECHANISMS OF GENE FUSION EVENTS 
 Gene fusions can occur in three ways. The most common method for developing gene fusions is 
through balanced chromosomal translocations. Balanced chromosomal translocations are when an arm 
of the chromosome swaps places with an arm of another chromosome. Depending on the location of 
the swap, this could cause gene fusion events in both chromosomes. The Philadelphia Chromosome 
(BCR-ABL) is a balanced chromosomal translocation between chromosomes 9 and 22.  
 Intrachromosomal deletions and inversions (Soda, 2007; Demichelis, 2007) are also able to 
form gene fusion events. An example of a gene fusion event formed from a deletion is the TMPRSS2-
ERG fusion found in many cancers, but especially recurrent in prostate cancer. This fusion is caused by 
a deletion on chromosome 21 q22.2-3. This fusion is found in approximately half of all prostate cancers 
and contain many different junction sites causing different phenotypic effects (Perner, 2006; Clark, 
2007). Inversions are formed though double strand breakage within one chromosome. These inversions 
can be paracentric or pericentric, targeting loci across arms or within the same arm. An example of an 
intrachromosomal inversion is the MLL-CALM fusion in Acute Myeloid Leukemia (Wechsler, 2003), 
which is an inversion of the 11th chromosome at arms q14 and q23.  
  The gene fusion event can cause cancer in several ways. First, the gene fusion can form an 
oncogene, such as the BCR-ABL (Vogelstein, 2013). Second, specific domains or nucleotides in a 
tumor suppressor can be truncated. Third, the tumor suppressor could be moved away from its 
promoter and near a new promoter, giving rise to new transcriptional events.   
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While little is known about the differences between gene fusion events in cancer and gene 
fusion events in normal samples, a few bioinformatics studies have attempted to shed some light on this 
issue. Gene fusions frequently involve kinases, particularly tyrosine kinases (Stransky 2014; Davare, 
2015), and as a result, kinase inhibitors have proven as a popular target for cancer therapy. These 
therapies mostly involve the kinases ALK, ETS, and RET (19). Transcription factors and histone 
methyltransferases have also been found at a higher probability than random chance. Complicating the 
matter, there have also been studies which found overlapping gene fusion events in both cancers and 
benign tissue. For example, in one study, the gene fusion VTI1A-TCF7L2 has been found in 42% of 
colon cancer but also in 29% of normal colon tissue and 25% of normal tissues from other organs 
(Nome, 2014). Normal gene fusions are hypothesized to be a way to increase proteomic diversity 
(Parra, 2006; Casado-Vela, 2013), but more research needs to be done to identify protein formation 
from gene fusion events on a large scale to determine other underlying causes and effects. 
1.3 CURRENT GENE FUSION DETECTION TOOLS 
1.3.1 TOOLS TO DETECT GENE FUSION EVENTS IN RNA-SEQ 
 Our increasing ability for high-throughput sequencing spawned a need for new computational 
methods to detect specific mutations in our sequences. Currently, there are numerous tools (Iyer, et al., 
2011, Ge, et al., 2011; Kim, et al., 2011; McPherson, et al., 2011; Abate, et al., 2012; Francis, et al., 
2012; Beccuti, et al., 2014; Fernandez-Cuesta, et al., 2015; Davidson et al., 2015) to detect specific 
gene fusion events directly from both paired-end and single read RNA-seq and Whole Genome 
Sequencing (WGS). These software methods are useful for detecting known gene fusion events as well 
as new gene fusion events through looking at the breakpoint junctions.  
 Most of these tools can be classified into three different types, as explained in Cararra, et al., 
2013. Whole paired-end based tools align the paired-end reads to a reference genome and use 
conflicting alignments to generate a set of fusion events. These events are then filtered based on a 
series of characteristics of real gene fusion events. Some of the tools that use this are deFuse 
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(McPherson, 2011) and FusionHunter (Li, 2011). In whole paired-end plus fragmentation methods, 
reads are also aligned to the genome but conflicting alignments are used to generate a new reference 
genome. In addition, the unaligned reads are also fragmented and realigned to the new fusion reference 
genome. TopHat-fusion (Kim, 2011), ChimeraScan (Iyer, 2011) and Bellerophontes (Abate, 2012) are 
methods that fall in this category. The final category is direct fragmentation based tools, which 
fragments the reads first and then aligns those fragments to a reference. FusionMap (Ge, 2011) and 
MapSplice (Wang, 2010) are examples of direct fragmentation fusion detection tools. 
 Independent studies that have analyzed these methods in depth for time complexity, accuracy 
and the number of false positives have given insight into the variance of gene fusion detection methods 
(Wang, 2013; Liu, 2016; Cararra, 2013). Unfortunately, there is very little overlap between software 
and there is a tendency for false positives in many of these programs. One method, FusionMap, 
balances specificity in negative datasets and sensitivity in positive datasets analyzed (Carrara, et al., 
2013). Despite the number of methods already developed, the best way to determine accurate gene 
fusion events with our current NGS technology is still in the process of being researched. The 
emergence of long-read sequencing could assist these methods in more accurately detecting fusion 
events, although many of these methods have not been tested on reads longer than 100 bp. In our 
analysis, we utilize the features produced by FusionMap, but may incorporate more software methods 
in the future. 
1.3.2 TOOLS TO DETECT MALIGNANT GENE FUSION EVENTS IN CANCER 
 Two methods currently exist to assess the oncogenic potential of the gene fusion event. 
Oncofuse is a supervised naïve bayes classifier, which utilizes intact domain information to determine a 
fusion events relationship with cancer (Shugay, et al., 2013). Oncofuse uses a very broad classifier, 
which contains gene fusion information from all cancers in one model. Accounting for the observation 
that gene fusion events are tissue-specific, Pegasus relies on a more advanced supervised learning 
method, boosted decision trees, to predict oncogenic potential in glioblastoma multiforme and 
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anaplastic large cell lymphoma (Abate, et al., 2014). Pegasus, uses a more specific model, contributing 
the idea that gene fusion events are cancer-specific. Both of these methods exhibit high-accuracy in 
fusion events through feature-based supervised learning. 
 While Oncofuse and Pegasus work well for their specific cases, an improved model is required. 
Preliminary analysis has discovered that for each cancer in this analysis (acute lymphoblastic leukemia, 
breast cancer and colorectal cancer), there is over one third of the fusion events which overlap between 
cancer and healthy (Figure 1). Previous studies have incorporated the data without reclassifying it as 
belonging to both categories or disposed of the data completely. To use and correctly classify this data, 
we employed a semi-supervised method which finds these overlapping fusion events, classifies them as 
unlabeled at initiation and attempts to classify each event based on the characteristics of similar events.  
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Figure 1: Classification count of gene fusion types for each cancer studied. 
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1.4 MACHINE LEARNING FOR CLASSIFICATION 
1.4.1 COMPARISON BETWEEN SUPERVISED AND SEMI-SUPERVISED METHODS 
 Both Pegasus and Oncofuse use a method called supervised machine learning, which trains the 
algorithm to learn whether a gene fusion event comes from cancer or healthy samples using already 
known examples from cancer and healthy samples. The mathematical model is then tested blindly on 
known examples, and the correctness of the algorithm is tested by comparing the number of guesses by 
the algorithm in each group to the actual number of examples in each group. Supervised learning 
algorithms are usually tested at 60% training set and a 40% testing set. For more information about the 
specific methods, equations and methods to assess an algorithms correctness, see the methods section.  
 Instead, for our method we use semi-supervised learning. Our algorithm utilizes both the 
unclassified (fusion events that occur in both healthy and cancer) and the unique events in cancer and 
healthy samples for training the model. To begin with, all data points are classified as unlabeled, cancer 
or healthy. The algorithm then tries to classify all of the unlabeled points, placing the top 20 best 
predictions back into the training set. The other predictions are returned to the unlabeled class and the 
process is repeated until all of the points are labeled.   
1.5 GENE EXPRESSION REGULATION IN GENE FUSION PATHWAY NEIGHBORS 
 Other more heavily studied somatic mutations (e.g. SNV and CNV) are known to affect gene 
expression in the cell (Haraksingh, 2013). Most of the gene expression variation that affects SNVs is 
associated with the frame-shift which happens if the mutation is located in the coding region. The 
connection between gene expression and copy number variants is more obvious, as it directly 
contributes to gene dosage in cells. However, due to our current lack of understanding of gene fusion 
events, this phenomenon has not been studied in gene fusion events.  
Through the analysis of the machine learning methods, we determined that some cancers 
performed better in our algorithm than others and as a result, we wanted to further explore why. The 
double strand breakage and chromosomal abnormality that results from can cause dysfunction within 
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the cell if circumstances are correct. In this case, we would need an intact, appropriate promoter as well 
as a start codon, a stop codon and no apparent frameshift.  
 A biological pathway is a series of molecules which produce a particular reaction within the 
cell. Members of these pathways can be affected by numerous pre and post-transcriptional and 
translational mechanisms such as gene dosage, gene expression, alternative splicing and post-
translational modification to name a few. One way to study the effects of the gene fusions on the 
pathway is to measure the gene expression of its neighbors. It is predicted there will be a ripple effect 
of these gene fusion events occurring in the genome, which will cause the genes surrounding the gene 
fusion event partners in a pathway to be differentially expressed. This ripple effect is predicted to 
present itself as differential expression of genes associated with cancer pathways of unique gene fusion 
pathway neighbors in both cancer and healthy samples. 
2 HYPOTHESES AND GOALS  
  The main goal of this project is to understand the role of gene fusion events in cancer and 
provide insights into the molecular mechanisms behind cancer-associated gene fusions. We achieve 
this goals through two specific aims. First, we develop a semi-supervised machine learning method for 
the classification of healthy and malignant gene fusion events. It is expected that as a result of our 
semi-supervised method leveraging the unlabeled gene fusion events as more related to the cancer or 
healthy sample, our model to classify the already known gene fusion events will improve.  
 Second, we explore the large-scale effects of gene fusions through pathway analysis genes. We 
hypothesize that we will see some overlapping pathways and genes. We then explore the unique 
significant genes who are pathway neighbors of gene fusion. We expect to derive much of the 
landscape of gene expression patterns for each of the gene fusion partners’ pathway neighbors. our 
second hypothesis is that we will find some genes within pathway neighbors that are differentially 
expressed, indicating that changes on the structural level also have an impact on the transcriptomic 
level, due to frame shift changes and partially intact domains. We also expect that many of these genes 
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will be involved with cancer pathways.  
3. METHODS 
3.1 NEXT GENERATION SEQUENCING ACQUISITION AND FUSION PREPROCESSING 
 Paired end RNA-seq samples were acquired from NCBI's Sequence Read Archive (SRA). 
Adapter sequences and low quality reads were trimmed using Trimmomatic Version 0.36 (Bolger, 
2014). Reads were omitted if they fell below 20 base pairs and nucleotides below a quality score 
(PHRED33) of 3 were removed. Trimmomatic scans the reads with a 4 base wide sliding window and 
cuts when the average quality per base drops below a PHRED33 quality score of 15. To detect fusion 
events, all trimmed FASTQ files were used as input for FusionMap (Ge, 2011). Human genome build 
37.3 was used to map fusion events to the genome. Features detected from FusionMap were used in 
both supervised and semi-supervised learning algorithms. Fusion events were screened for previous 
discovery as a recurrent gene fusion event in cancer using Chimera DB tissue search. 
3.2 DATASETS 
 To explore the breadth of cancers known to harbor gene fusions, Illumina paired end RNA-seq 
datasets from acute lymphoblastic leukemia (ALL), breast cancer (BC) and colorectal cancer (CRC) 
were obtained and analyzed using the above methodology. Samples were obtained from NCBI SRA for 
subsequent analyses. 
 ALL was used as a representative of the hematological cancers, for which gene fusion events 
have been well-characterized. As described in Almamun, et al., 2015, the dataset was comprised of 20 
pre-B ALL patient samples and 10 pre-BI and pre-BII samples isolated from human cord blood. 
Samples were obtained from NCBI SRA dataset SRP058414. A total of 534 gene fusion events are 
found, 209 occurring solely in cancer, 134 occurring solely in healthy samples and 189 of unknown 
origin as they were found in both cancer and healthy samples.  
 Colorectal cancer was used as a representative of a smaller matched study. As explained in 
Kim, et al., 2014, the dataset was comprised of 18 primary CRC tumors and 18 matched normal colon 
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samples. Samples were obtained from NCBI SRA dataset SRP029880. A total of 226 gene fusion 
events were found with 69 occurring uniquely in cancer, 12 occurring uniquely in healthy samples and 
145 of unknown origin. 
 Breast cancer was used as a representation of a large scale matched study. As explained in 
Varley, et al., 2014, the dataset was comprised of 28 breast cancer cell lines, 42 triple negative breast 
cancer (TNBC) primary tumors, 42 estrogen receptor positive (ER+) breast cancer primary tumors, and 
56 healthy breast tissue samples. Triple negative breast cancer lacks expression of the estrogen 
receptor, progesterone receptor and HER2/neu. ER+ samples have the estrogen receptor expressed. 
Within these samples, there are 26 matched ER+ samples and 17 matched TNBC samples. Except 
where noted, most analyses are performed just using the matched samples. Samples were obtained from 
SRA dataset SRP042620. For the matched dataset, a total of 1773 gene fusion events were found with 
833 occurring solely in cancer, 194 occurring in healthy samples and 744 of unknown origin occurring 
in both cancer and healthy samples. 
3.3 FEATURES REPRESENTING GENE FUSION EVENTS 
 Features (Table 1) generated from FusionMap were used to detect structural characteristics of 
gene fusion events. To account for the importance of the relationship between the fusion partners, our 
group developed a gene ontology classification system for each fusion partner separately. Each gene 
ontology section (Biological Process, Cellular Component and Molecular Function) is a series of 
graphs, each with a node and a vector connecting the node to its ancestors and descendants. We found 
all descendants of the three sections up to three descendants away from the top node (Biological 
Process, Cellular Component, and Molecular Function) (Figure 2). Due to the large number of genes in 
the top node, the top node was not included in this analysis. Due to the large number of GO terms and 
high level of redundancy amongst the terms, any GO term with a distance of greater than 3 from the 
root node was omitted from the feature set. For each given gene fusion event, involving a pair of genes, 
and a given GO-term the numerical feature corresponding to that term was 0 if neither of the genes 
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were associated with this GO term, 1 if only one of the genes was associated with the GO term, and 2 if 
both genes were associated with the GO term. The resulting feature set includes 36,032 features, a large 
number given a relatively small training set, which could contribute to severe underfitting of our 
model. 
 Since we have a large feature set, it is proposed that we could use dimensionality reduction to 
decrease the number of features. Gene ontology terms have an extremely repetitive vocabulary and as a 
result, our model could be improved by some techniques from natural language processing, most 
specifically topic modeling. From these methods, we were able to cut down the number of features 
from 36032 features for each dataset to around 50 features for each dataset.  
3.4 SUPERVISED LEARNING METHODS  
As a baseline to explore our novel semi-supervised algorithm, supervised learning classification 
algorithms Naive Bayes, SVM and Random Forest were used. For this set of experiments, ambiguous 
gene fusion events, belonging to both cancer and healthy samples, were not used.   
Naive Bayes bases decisions on the idea that given a particular classification, what is the 
probability that a particular attribute can occur? Naïve Bayes was selected because this is the model 
that Oncofuse uses in for its datasets. The classifier (Mitchell, 1998) assumes conditional independence 
of X containing n attributes, which are conditionally independent of one another given Y. When a new 
instance of X is introduced, Naive Bayes will calculate the probability that Y will take on any value 
given the attribute values of the new X and the distributions of P(Y), and P(Xi|Y). 
 Support vector machines (Cortes, Vapnik, 1995) are a classification algorithm which first 
determines the points that lie closest to the selected decision boundary. These points may be ambiguous 
in terms of whether they belong to the positive or negative datasets. These points are denoted as the 
support vectors, and the maximum margin from the distance between the support vectors and the 
decision boundary is determined. This is established through rotation of the entire dataset. The type of 
support vector machine used here is called radial basis function, which works well for non-linear 
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datasets. The classical linear SVM solves the following optimization problem: 
⎩
⎪
⎨
⎪
⎧12 ‖ 𝜔𝜔‖2 + 𝐶𝐶�𝜉𝜉𝑛𝑛𝑁𝑁
𝑛𝑛=1
→ 𝑚𝑚𝑚𝑚𝑚𝑚
𝜔𝜔,𝑏𝑏,𝜉𝜉,
𝑡𝑡𝑛𝑛(𝜔𝜔𝑇𝑇𝑥𝑥𝑛𝑛 + 𝑏𝑏) ≥ 1 − 𝜉𝜉𝑛𝑛,
𝜉𝜉𝑛𝑛 ≥ 0  
where 𝑥𝑥𝑛𝑛 is a feature vector for n-th data point in our dataset, 𝑡𝑡𝑛𝑛 ∈ {−1, +1} is it’s label, 𝜔𝜔 is the weights 
vector, 𝑏𝑏 is a bias, 𝜉𝜉𝑛𝑛 is a cost for misclassifying sample which depends upon distance from the margin and 𝐶𝐶 is 
regularization parameter. 
Random forests (Breiman, 2001) uses a combination of decision trees and bagging in order to 
determine the class of a particular vector. For a specific number of trees, in our case 100, a number of 
features, in our case 3, are selected at random. With these three features, a decision tree is created in 
order to classify the sample as belonging to cancer or normal samples. The best predictors for each 
node is selected from random subsets. Class is predicted based on majority vote of the resulting trees. 
As a result of their random nature, random forest models work great for heterogeneous datasets. 
3.5 SEMI-SUPERVISED LEARNING METHODS 
 Semi-supervised learning (Ratsaby and Venkatesh, 1995) is a class of algorithms for which you 
only know some of the classifications of the samples before you begin the algorithm. Since random 
forest was the highest performing method, it was applied to our semi-supervised method to determine 
the correct classification for each unlabeled point. The top 20 definitive points were kept and placed 
back into the training set. The process was repeated until all points were classified. Finally, the testing 
set here is comprised of only healthy and cancer fusion events that are not overlapping between the two 
groups. 
3.6 MACHINE LEARNING ALGORITHM ASSESSMENT 
 Our algorithm will likely classify some fusion events right and some fusion events wrong. To 
determine the best algorithm for each dataset, we measure the true positives, true negatives, false 
positives and false negatives. Table 2 illustrates these points. When a positive data point is correctly 
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predicted as a positive data point, it is referred to as a true positive. When a negative data point is 
correctly predicted as a negative data point, it is referred to as a true negative. When a positive data 
point is incorrectly predicted as a negative data point, it is referred to as a false negative. When a 
negative data point is incorrectly predicted as a positive data point it is referred to as a false positive. 
 Through these measurements, we can now determine various metrics of our algorithm. 
Accuracy is the total percentage the algorithm gets correct. It is normalized by the total size of the 
dataset and includes all positives and all negatives.  
𝐴𝐴 = 𝑇𝑇𝑃𝑃 + 𝑇𝑇𝑁𝑁
𝑇𝑇𝑃𝑃 + 𝐹𝐹𝑃𝑃 + 𝑇𝑇𝑁𝑁 + 𝐹𝐹𝑁𝑁 
Precision is the total percentage of the true positives when taking into account all of the positive 
values. For our situation, this translates into the number of times the algorithm guessed that the gene 
fusion event was cancer and it was correct, compared to the total amount of times that it guessed 
cancer. 
𝑃𝑃 = 𝑇𝑇𝑃𝑃
𝑇𝑇𝑃𝑃 + 𝐹𝐹𝑃𝑃  
Recall is the total percentage of the true positive samples that were selected by the algorithm 
compared to the total number of actually positive samples. For our situation, this translates to the 
number of times our algorithm was able to extract the positive values out of all of the positive values. 
𝑅𝑅 =  𝑇𝑇𝑃𝑃
𝑇𝑇𝑃𝑃 + 𝐹𝐹𝑁𝑁 
 Finally, we use the F-score as a combined metric to assess the algorithm’s efficiency. It 
combines the scores for both precision and recall.  
𝐹𝐹 = 2 𝑃𝑃 𝑥𝑥 𝑅𝑅
𝑃𝑃 + 𝑅𝑅 
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3.7 RNA-SEQUENCING ANALYSIS 
 Gene expression analysis was performed using the Tuxedo Suite. Tophat (Trapnell, 2009) was 
used to align reads to the genome, Cufflinks (Trapnell, 2010; Trapnell, 2013) was used to quantify the 
total number of Fragments per Kilobase of transcript per Million mapped reads (FPKM) which 
indicates the expression values for all of the groups. This is a normalized measure which takes 
normalizes the fragment found and to the length of the read. Tophat accepts RNA-seq reads data and 
then aligns the reads to a known genome. This will enable us to determine annotation for the already 
known genes. The maximum, average and median FKPM were taken for all groups, as well as a p-
value to assess significance of the expression level for particular genes.  
3.7.1 PATHWAY ANALYSIS 
  Reactome (Fabregat, 2016; Milacic, 2016) pathway neighbors of either fusion partner was 
determined using Pathway Commons (Cerami, 2011) neighborhood function. The Reactome database 
was selected over other commonly used pathway databases (KEGG, PANTHER, etc.) because of its in- 
depth biochemical pathways. Initial analysis showed the glycolysis pathway may be affected and we 
were interested in more specific steps of glycolysis than KEGG could provide. Neighbors were selected 
at a distance of two or less nodes upstream or downstream from the fusion partner. Delta FKPM was 
detected through subtracting the averaged healthy from the averaged normal FPKM. The most 
significant neighbors were detected by calculating the mean and standard deviation for the healthy 
neighbors and then applying it to the cancer neighbors to find if there are any neighbors fall outside of 
the normal distribution of the healthy neighbors. Cancer fusion neighbors with healthy-normalized z 
scores greater than 3σ were explored further through literature review and also compared to the normal 
fusion neighbors. Distribution of both healthy and cancer fusion neighbors were determined and 
enrichment was calculated using the following formula. Overlapping genes between cancers were 
identified to assess potential drug targets. Unique genes within cancers and between cancer and healthy 
from the same tissue were also assessed.  
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Enrichment of genes was determined via the software program Enrichr (Chen, 2013). Enrichr is a 
pathway analysis tool which uses Fisher’s exact test for detecting which pathways are enriched in a 
phenotype of choice. We chose this algorithm because it tends to not bias towards large pathways and it 
allows us to specifically pick the commonly known pathway database of our choice. In our case, we 
used Reactome. A p-value is determined based on Fisher’s exact test, then a z-score is calculated based 
on intuition. Finally, the two methods are put together to create one combined score: 
𝑐𝑐 = log(p) z 
 In this equation, c is the combined score, p is the p-value which is determined by Fisher’s exact 
test, and z is the deviation of the pathway from the expected rank as developed through intuition. 
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Table 1: FusionMap features used for machine learning analysis 
FusionMap Features Original Type? Definition 
Seed Count Numerical Unique fusion junction cut sites  
Rescued Count Numerical Number of reads for a specified fusion.  
Position1 (5') Numerical 
What position is it at in the genome Position2 (3') Numerical 
Exon Number1 (5') Numerical 
What is the exon number? Exon Number2 (3') Numerical 
Strand Categorical Does it come from a positive or negative strand? 
Splice Pattern Class Categorical What is the specific pattern at the fusion? 
Frame Shift Class Categorical Is there a frameshift mutation? 
Breakpoint distance Numerical Distance between original cut sites. 
On Exon Boundary Categorical Does this lie on an exon boundary? 
Chromosome number 1 (5') Numerical 
Original chromosome number for each gene. Chromosome number 2 (3') Numerical 
Label Categorical (Target) Does this event belong to cancer or healthy? 
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Figure 2: Algorithm of calculating Gene Ontology (GO) features defined. Each of the three sub-
categories of Gene Ontology was treated as a multi-layer graph. The top three GO layers were used as 
our functional features. 
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Figure 3: Example of procedure of self-iterative semi-supervised learning, represented in Leukemia 
dataset. Leukemia samples are trimmed and ran through FusionMap software and then separated into 
only present in healthy, only present in cancer or unlabeled (present in both). The unlabeled points are 
classified by random forest. Then, the top 20 most unambiguous points are reintegrated into the 
training set and the rest are returned to the unlabeled class. The process is repeated until all of the 
unlabeled points are labeled as either cancer or healthy. 
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Table 2: Machine learning assessment for semi-supervised and supervised learning 
  Actual 
  Cancer Healthy 
pr
ed
ic
te
d 
Cancer True Positive False Positive 
Healthy False Negative True Negative 
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4. RESULTS 
4.1 PRELIMINARY MACHINE LEARNING ANALYSIS OF ACUTE LYMPHOBLASTIC 
LEUKEMIA 
 To test how well each supervised algorithm performed, we subjected our supervised Naïve 
Bayes, Support Vector Machines (SVM) and random forest on our acute lymphoblastic leukemia 
dataset, before applying feature selection. We also applied our semi-supervised algorithm to this 
analysis. From these results, it was determined that random forest performed the best out of all of the 
supervised algorithms, since it had the best recall (77.78%), accuracy (84.06%) and F-score (79.25%). 
Naïve Bayes performed the worst in accuracy, precision and F-score. Support vector machines had the 
best precision (97.05%), but also had the worst recall (61.11%). Since our best algorithm for this 
dataset was random forest, the self-iterating semi-supervised random forest was then applied to this 
dataset. Using this algorithm gave us an increase of three to six percentage points in accuracy. It also 
the highest accuracy (87.68%) as compared with the supervised models, as well as the highest F-score 
(82.47%). (Table 3) 
 
Table 3: Supervised and semi-supervised learning of Acute Lymphoblastic Leukemia, pre-feature 
selection. Values in red indicate worst performance. Values in green indicate best performance 
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4.2 MACHINE LEARNING ANALYSIS OF CANCER DATASETS WITH FEATURE 
SELECTION 
Since our best working algorithms for ALL were our semi-supervised and supervised random 
forest algorithms, it was decided to apply those algorithms to matched breast cancer dataset. Using a 
matched dataset will allow us to determine if our algorithm works on matched patients. When breast 
cancers were separated into ER+ (estrogen receptor expressed) and triple negative breast cancer 
(lacking estrogen receptor, progesterone receptor and HER2/neu expression), we had high accuracy and 
F-measure using only supervised random forest (Table 4). This is before using our topic modeling 
feature selection at 37 total Gene Ontology topics along with our FusionMap features. All future 
machine learning protocols will use breast cancer phenotypes separately. Figure 4 summarizes 
accuracy and F-score for random forest without feature selection amongst all cancers. Not including 
feature selection, ER+ had an accuracy of 89.74% and an F-score 82.61%. TNBC had an accuracy of 
83.33% and an F-score of 83.23%. Leukemia had an accuracy of 85.4% and an F-score of 81.93%. 
Colorectal cancer had an accuracy of 84%. Colorectal cancer had a very low gene fusion normal count 
(only 12 gene fusions were detected as being unique in normal colon tissue), which is why we were not 
able to obtain an F-score for colorectal cancer. 
While it may be more accurate to have many features, it doesn’t make sense for biological 
clarity to have so many redundant features. Figure 5 summarizes supervised random forest F-score and 
accuracy for all cancers with 37 total Gene Ontology features derived from topic modeling feature 
selection and FusionMap features. Our overall performance for supervised random forest was 
consistent across cancers. Including feature selection, ER+ had an accuracy 80.3% and an F-score of 
61.01%. TNBC had an accuracy of 83.33% and an F-score of 83.23%. Leukemia had an accuracy of 
86.4% and an F-score of 82.5%. Colorectal cancer had an accuracy of 84%. Colorectal cancer had a 
very low gene fusion normal count (only 12 gene fusions were detected as being unique in normal 
colon tissue), which is why we were not able to obtain an F-score for colorectal cancer. In general, this 
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model didn’t work as well as the model without feature selection, but it has the benefit of only being 
around 50 features as opposed to over 30,000. This is beneficial for two reasons. First, it will speed up 
our algorithm greatly. Second, it will make this more biologically relevant, because we are combining 
all similar features into one. 
Next, we tried semi-supervised learning using the above methods. Figure 6 shows the F-score 
and accuracy performance of our semi-supervised method using feature selection through topic 
modeling. Including feature selection, ER+ had an accuracy 83.7% and an F-score of 68.85%. TNBC 
had an accuracy of 83.33% and an F-score of 83.23%. Leukemia had an accuracy of 83.4% and an F-
score of 79.01%. Colorectal cancer had an accuracy of 84%. Colorectal cancer had a very low gene 
fusion normal count (only 12 gene fusions were detected as being unique in normal colon tissue), 
which is why we were not able to obtain an F-score for colorectal cancer. Overall, our semi-supervised 
model performed about equally with the supervised model, indicating that we may need some different 
features in order to improve the score. 
 
Table 4: Supervised random forest for breast cancer subsets 
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Figure 4: Supervised random forest for all cancers studied with no topic modeling included. Blue 
indicates accuracy and red indicates F-score  
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Figure 5: Supervised random forest for all cancers studied with LDA topic modeling included. Blue 
indicates accuracy and red indicates F-score  
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Figure 6: Semi-supervised random forest for all cancers studied with LDA topic modeling included. 
Blue indicates accuracy and red indicates F-score  
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4.3 OVERALL GENE FUSION ANALYSIS 
 To begin to understand the landscape of the gene fusion events detected using FusionMap in the 
three cancers selected, an overall gene fusion pathway analysis and literature review was performed for 
all of the gene fusions retrieved. This will assure us that these gene fusion events are not artifacts of 
next-generation sequencing errors or false positives. Out of all of the gene fusion events in the three 
datasets, only HLA-A-HLA-B (Kimura, 2006) from colorectal cancer, POLA2-CDC42EP2 (Kang, 
2016), and fusions involving FGF1-3 (Kumar-Sinha, 2015), have been previously identified as 
recurrent gene fusion events as reported by ChimeraDB. However, we also found genes that are family 
members with genes known as recurrent gene fusion events such as ETV2, which is in the ETS 
transcription factor family, related with ETV6, which is involved in a known gene fusion event in ALL 
(TEL-AML1). The other gene fusion events could either be false positives or novel gene fusion events. 
More analysis would be needed with another gene fusion software program to determine whether or not 
there are false positives within these datasets and determining overlap between the software programs. 
4.4. GENE FUSION PATHWAY ANALYSIS 
 Pathway analysis of all of the gene fusion events were determined via Enrichr (Chen, 2013). 
Enrichr was used as an alternative to Gene Set Enrichment Analysis (Subramanian, 2005) and the 
multitude of other enrichment software programs for a few reasons. Firstly, both gene set enrichment 
analysis and other enrichment programs have a tendency to be biased towards large gene sets. Enrichr 
uses a more advanced algorithm to prevent this. The algorithm first computes the p-value from Fisher’s 
exact test, which indicates the likelihood that detecting those focus genes in the pathway is not due to 
random chance (p-value). This method is used among many of the enrichment software programs. 
Additionally, it computes the deviation of the expected rank, which was developed based on intuition 
and through testing on multiple datasets, compared with the actual rank (z-score).  
Secondly, Enrichr uses thirty-five well-known databases as its gene set libraries. For 
comparison purposes, GSEA uses a set of seven gene set libraries that are primarily made through 
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manual curation. As a result, in Enrichr the user can select which pathway database to use in order to 
obtain consistency with the rest of their experiment. For this instance, Reactome pathways were used in 
order to stay consistent with later studies. 
All of our gene fusion events were used as queries for the Enrichr software. In order to view the 
differences between cancer and normal tissue or cells in each cancer, gene fusion events were divided 
based on cancer type and also whether the gene fusion event was associated in our dataset with normal 
or cancer. Unclassified gene fusion events were omitted from this analysis. 
Figures 7-12 show the results from this study. As expected, due to the tissue-specific nature of 
gene fusion events, enriched pathways rarely overlap between the genes involved in gene fusions 
across cancers and between healthy and malignant tissue or cells. Tables 5-10 show specific genes in 
each dataset associated with each pathway. From these tables, it has been observed that there are very 
few overlapping gene fusion associated genes that contribute to the enrichment of these pathways. This 
can be said for genes that are overlapping between cancer fusions and healthy fusions, as well as genes 
that span cancers. This may fuel the argument that gene fusions are tissue specific. Many of the 
pathways that are enriched are similar within the group, as seen with the ALL cancer fusion partners. 
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Figure 7: Enriched pathways for genes associated with cancer gene fusion events in ALL as 
determined by Enrichr. Length of bar directly correlates to combined score as generated by Enrichr.
 
Figure 8: Enriched pathways associated with healthy gene fusion events in ALL as determined by 
Enrichr ranked by enrichment score. Length of bar directly correlates to combined score as generated 
by Enrichr. 
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Table 5: Details of enriched pathways in gene fusions represented in acute lymphoblastic leukemia. P-
value represents the p-value as determined by Fisher’s exact test. Z-score is the z-score determined by 
the enrichr algorithm which is based on intuition and combined is the combined score between the p-
value and the z-score. 
 
 
 
 
 
 
 
 
Term P-value Z-score Combined Genes
Synthesis and interconversion of 
nucleotide di- and triphosphates 0.001 -2.100 2.609 RRM2;NME4;AK7
E2F mediated regulation of DNA 
replication_Homo sapiens 0.002 -2.109 2.518
POLA2;RRM2; 
E2F1
Chromosome Maintenance_Homo 
sapiens 0.003 -2.061 2.262
POLA2;APITD1; 
SMARCA5;TERF2
Inhibition of replication initiation of 
damaged DNA by RB1/E2F1 0.004 -2.048 2.247 POLA2;E2F1
Oxygen-dependent proline 
hydroxylation of Hypoxia-inducible 
Factor Alpha 0.008 -2.160 1.711 UBE2D2;HIF1A
G1/S-Specific Transcription_Homo 
sapiens 0.007 -2.090 1.655 RRM2;E2F1
Cell Cycle 0.035 -2.344 1.272
POLA2;APITD1;   
RRM2;STAG; 
DMC1;SMARCA5;
E2F1;TERF2
Cellular responses to stress 0.012 -2.319 1.261
PRKAA1;UBE2D2;
E2F1;CHMP4A; 
BMI1;TERF2;HIF1
A
Regulation of Hypoxia-inducible 
Factor (HIF) by oxygen 0.015 -2.080 1.131 UBE2D2;HIF1A
Cellular response to hypoxia 0.015 -2.050 1.114 UBE2D2;HIF1A
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Table 6: Details of enriched pathways in gene fusions represented in healthy blood. P-value represents 
the p-value as determined by Fisher’s exact test. Z-score is the z-score determined by the enrichr 
algorithm which is based on intuition and combined is the combined score between the p-value and the 
z-score. 
 
  
 
 
Term P-value Z-score Combined Genes
CREB phosphorylation through the 
activation of Ras 0.001 -2.136 3.985
PDPK1;CAMK2A;
CAMK2G
Sialic acid metabolism 0.001 -2.099 3.915
NEU3; 
ST6GALNAC4; 
ST6GALNAC6
Post NMDA receptor activation events 0.001 -2.098 3.914
PDPK1;CAMK2A;
CAMK2G
Signaling by ERBB4 0.003 -2.542 3.821
NR4A1;NCSTN; 
ITCH;PDPK1; 
CAMK2A;IL2RG; 
CAMK2G
Activation of NMDA receptor upon 
glutamate binding and postsynaptic 
events 0.002 -2.018 3.756
PDPK1;CAMK2A;
CAMK2G
Signaling by Insulin receptor 0.037 -2.287 2.747
PDPK1;CAMK2A; 
IL2RG;ATP6V0C; 
CAMK2G
CREB phosphorylation through the 
activation of CaMKII 0.004 -1.833 2.727
CAMK2A; 
CAMK2G
Innate Immune System 0.019 -2.259 2.713
NR4A1;ITCH; 
PDPK1;ARPC1B; 
CAMK2A;ARPC4; 
NLRP1;IL2RG; 
MAP3K14; 
CAMK2G
Signaling by SCF-KIT 0.043 -2.240 2.690
NR4A1; 
PDPK1;CAMK2A; 
IL2RG;CAMK2G
Downstream signaling of activated 
FGFR4 0.045 -2.235 2.684
NR4A1; PDPK1; 
CAMK2A;IL2RG; 
CAMK2G
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Figure 9: Enriched pathways associated with cancer gene fusion events in breast cancer as determined 
by Enrichr. Length of bar directly correlates to combined score as generated by Enrichr. 
 
Figure 10: Enriched pathways associated with healthy gene fusion events in breast cancer as 
determined by Enrichr. Length of bar directly correlates to combined score as generated by Enrichr. 
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Table 7: Details of enriched pathways in gene fusions represented in breast cancer. P-value represents 
the p-value as determined by Fisher’s exact test. Z-score is the z-score determined by the enrichr 
algorithm which is based on intuition and combined is the combined score between the p-value and the 
z-score. 
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Table 8: Details of enriched pathways in gene fusions represented in healthy breast tissue. P-value 
represents the p-value as determined by Fisher’s exact test. Z-score is the z-score determined by the 
enrichr algorithm which is based on intuition and combined is the combined score between the p-value 
Term P-value Z-score Combined Genes
Hemostasis 0.0000 -2.1481 13.8074
DGKG;LGALS3BP;APP;ITGAM;SPARC;SERPINE2;PIK3CD;KIF12;F11R; 
ITGAL;CLU;KIF5C;AKT2;PHACTR2;KIF21A;APLP2;SERPINF2;KIF25; 
ACTN4;MIF;GAB2;TUBA4A;SLC7A5;PRKAR1B;STIM1;KIFC1;KIF16B; 
SOS1;FN1;ALDOA;RAF1;DOCK2;MGLL;CD44;HDAC2;ITPR1;ITPR2; 
GATA3;PIK3R1;LRRC16A;PRKCZ;LRP8;GNAI2;RAP1B;RAP1A;GNG4; 
GNA12;ABL1;FLNA;STX4;FYN;CD74;CREBBP;HSPA5;NOS2;PCDH7;FN1; 
ATP2B2;PTK2;P2RX7;GNB2;GNAS;ESAM;GNB5;BCAR1
Platelet activation, 
signaling and 
aggregation 0.0000 -2.1525 12.7987
DGKG;LGALS3BP;APP;SPARC;ITPR1;ITPR2;PIK3CD;PIK3R1;PRKCZ; 
CLU;GNAI2;RAP1B;RAP1A;GNG4;AKT2;GNA12;FLNA;PHACTR2;STX4; 
FYN;HSPA5;APLP2;PCDH7;SERPINF2;FN1;ACTN4;GAB2;PTK2;TUBA4A;
GNB2;GNB5;PFN1;ALDOA;RAF1;SOS1;MGLL;BCAR1
Metabolism of 
proteins 0.0002 -2.1278 6.4096
APP;ARF1;B4GALT1;PIGN;HSCB;ACTB;RPS15;TFG;RPL18A;KIF5C; 
TUBB3;PMPCA;RPL38;CTSD;SPTAN1;NUP214;EIF5B;ALG8;SEC13; 
NUP210;IGFBP5;MMP2;H2AFX;ALG12;ANK1;TUBA4A;DDOST;ARFGAP1;
SUMF1;EEF1G;DPM1;CTAGE5;EEF1A2;RPL37A;EXOC3;NUP54;PABPC1; 
SEC22B;PFDN5;ARF5;SLC25A6;LTF;RAB1A;COPA;CPB1;TOMM40;GNAI2;
GANAB;GYLTL1B;MTA1;GMDS;OS9;BGLAP;GNG4;LMAN2;NEU1;LMNA;
RPL13;CD59;CCT7;RAE1;ST3GAL1;ST3GAL3;SPTBN2;GALNT7;FN3K; 
DYNC1H1;ARFGEF2;NOP58;XBP1;GSN;MUC16;HSPA5;EDEM1;FUCA1; 
PCGF2;TRAPPC10;STAT3;EIF2AK3;TIMM44;TRAPPC9;EEF2;GNAO1; 
MGAT4C;STAG2;EIF3L;GLB1;GNB2;GOLGB1;EIF3G;MSRB2;EIF3H;GNB5; 
TGFBI;EIF3D;EIF3A
Asparagine N-linked 
glycosylation 0.0002 -2.1059 6.3435
RAB1A;ARF1;COPA;B4GALT1;GANAB;GMDS;TFG;OS9;LMAN2;NEU1; 
CD59;ST3GAL1;SPTAN1;ST3GAL3;SPTBN2;DYNC1H1;ALG8;SEC13; 
EDEM1;FUCA1;TRAPPC10;ALG12;TRAPPC9;ANK1;ARFGAP1;DDOST; 
DPM1;MGAT4C;CTAGE5;GLB1;GOLGB1;SEC22B;ARF5
Collagen formation 0.0002 -1.9918 5.9997
LAMB3;COL22A1;PLOD1;MMP20;COL1A1;COL2A1;COL5A1;COL4A2; 
COL4A4;COL6A1;COL9A1;COL20A1;COL6A3;P4HB;CTSB;PLEC
Extracellular matrix 
organization 0.0004 -2.0721 5.4984
DDR1;FBN3;SPARC;PTPRS;ITGAM;ELN;PLOD1;F11R;ITGAL;MMP20; 
CAPN7;CDH1;NCAM1;CTSD;CTSB;LAMB3;COL22A1;MMP2;FN1;BGN; 
COL1A1;COL2A1;COL4A2;COL5A1;COL4A4;COL6A1;COL9A1;COL20A1; 
COL6A3;P4HB;AGRN;MATN4;CD44;PLEC
Integration of energy 
metabolism 0.0010 -1.9957 4.1710
PFKFB1;KCNJ11;ABCC8;ADIPOQ;ITPR1;CACNA1A;ITPR2;ACACA; 
GNAI2;CACNB3;RAP1A;PRKAR1B;GNG4;GNB2;GNAS;GNB5;SLC25A6
Membrane 
Trafficking 0.0014 -2.0586 4.1442
RAB1A;APP;ARF1;NBAS;COPA;TFRC;STX16;CLTB;KIF12;PIK3C2A;TFG; 
KIF5C;AKT2;LMAN2;SFN;STX4;KIF21A;CD59;SPTAN1;AP1M2;CYTH1; 
SPTBN2;DYNC1H1;SEC13;TRAPPC10;M6PR;KIF25;DTNBP1;AP3B1;SNF8;
TRAPPC9;PUM1;ANK1;ARFGAP1;GJB2;CTAGE5;KIF16B;GOLGB1;EXOC3;
TRIP11;SEC22B;ARF5;PICALM
Apoptotic cleavage of 
cellular proteins 0.0011 -1.9554 4.0866 OCLN;GSN;CDH1;LMNA;ACIN1;SPTAN1;PTK2;PLEC;LMNB1
Assembly of collagen 
fibrils and other 
multimeric structures 0.0012 -1.9317 4.0371
COL1A1;COL2A1;LAMB3;COL5A1;COL4A2;COL4A4;COL6A1;COL6A3; 
CTSB;PLEC;MMP20
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and the z-score. 
 
 
Term P-value Z-score Combined Genes
Extracellular matrix organization 5.47E-05 -2.072 10.351
COL28A1;FGB;COL18A1; 
LAMA3;LAMC2;LTBP3; 
HSPG2;FBLN5;MMP14; 
COL1A2;COL8A2;AGRN; 
CTSD;CTSB;PLEC
Assembly of collagen fibrils and 
other multimeric structures 3.97E-05 -1.990 10.202
COL18A1;COL1A2;LAMA3; 
COL8A2;LAMC2;CTSB;PLE
C
Retinoid metabolism and 
transport 9.12E-06 -1.973 10.116
RBP4;LRP1;APOA1;LPL; 
BCO2;AGRN;HSPG2
Metabolism of fat-soluble 
vitamins 2.84E-05 -1.954 10.019
RBP4;LRP1;APOA1;LPL; 
BCO2;AGRN;HSPG2
Collagen formation 9.05E-05 -1.946 9.720
COL28A1;COL18A1;COL1A2
;LAMA3;COL8A2;LAMC2;C
TSB;PLEC
Binding and Uptake of Ligands 
by Scavenger Receptors 3.65E-05 -1.867 9.571
COL1A2;AMBP;LRP1;ALB; 
STAB1;SAA1;APOA1;FTL
Caspase-mediated cleavage of 
cytoskeletal proteins 8.65E-05 -1.906 9.521 GSN;MAPT;VIM;PLEC
Platelet degranulation 6.43E-05 -1.874 9.362
FGB;AHSG;APLP2;APOH; 
ALB;PSAP;IGF2;APOA1; 
CLU
Visual phototransduction 3.62E-05 -1.817 9.315
RBP4;GUCY2D;LRP1; 
RGS9BP;LPL;APOA1;BCO2;
AGRN;HSPG2
Response to elevated platelet 
cytosolic Ca2+ 8.99E-05 -1.840 9.189
FGB;AHSG;APLP2;APOH; 
ALB;PSAP;IGF2;APOA1; 
CLU
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Figure 11: Enriched pathways associated with cancer gene fusion events in colorectal cancer as 
determined by Enrichr. Length of bar directly correlates to combined score as generated by Enrichr. 
 
Figure 12: Enriched pathways associated with healthy gene fusion events in colorectal cancer as 
determined by Enrichr. Length of bar directly correlates to combined score as generated by Enrichr. 
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Table 9: Details of enriched pathways in gene fusions represented in colorectal cancer. P-value 
represents the p-value as determined by Fisher’s exact test. Z-score is the z-score determined by the 
enrichr algorithm which is based on intuition and combined is the combined score between the p-value 
and the z-score. 
 
 
 
 
 
 
 
 
 
Term P-value Z-score Combined Score Genes
Interferon Signaling 0.008 -2.078 2.065 GBP7;IFI27;GBP4;NUP160
EPHB-mediated forward 
signaling 0.013 -2.011 1.999 ACTB;ACTG1
RHO GTPases Activate 
Formins 0.011 -1.978 1.965 NUP160;ACTB;ACTG1
EPH-Ephrin signaling 0.007 -1.976 1.964 VAV3;ACTB;ACTG1
COPI-independent Golgi-
to-ER retrograde traffic 0.007 -1.947 1.935 DCTN2;RAB6A
Regulation of actin 
dynamics for phagocytic 
cup formation 0.007 -1.931 1.919 VAV3;ACTB;ACTG1
Golgi-to-ER retrograde 
transport_Homo sapiens 0.010 -1.923 1.911 DCTN2;KIF13B;RAB6A
RHO GTPases Activate 
WASPs and WAVEs 0.010 -1.902 1.891 ACTB;ACTG1
Metabolism of 
carbohydrates 0.026 -2.121 1.863 PYGB;AKR1A1;HAS2;NUP160
Fcgamma receptor 
(FCGR) dependent 
phagocytosis 0.013 -1.870 1.858 VAV3;ACTB;ACTG1
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Table 10: Details of enriched pathways in gene fusions represented in healthy colon tissue. P-value 
represents the p-value as determined by Fisher’s exact test. Z-score is the z-score determined by the 
enrichr algorithm which is based on intuition and combined is the combined score between the p-value 
and the z-score. 
 
 
 
 
 
 
 
 
 
Term P-value Z-score Combined Genes
SLC-mediated transmembrane 
transport 0.012 -1.983 5.452 SLC44A1;SRI
Sodium/Calcium exchangers 0.008 -1.903 5.232 SRI
Amine compound SLC 
transporters 0.021 -2.012 5.204 SLC44A1
Defective GALNT12 causes 
colorectal cancer 1 (CRCS1) 0.013 -1.888 5.192 MUC13
Termination of O-glycan 
biosynthesis_Homo sapiens 0.018 -1.965 5.144 MUC13
Defective GALNT3 causes familial 
hyperphosphatemic tumoral 
calcinosis (HFTC) 0.013 -1.855 5.099 MUC13
Defective C1GALT1C1 causes Tn 
polyagglutination syndrome 
(TNPS) 0.014 -1.855 5.099 MUC13
Synthesis of PC 0.014 -1.825 5.018 SLC44A1
Inflammasomes 0.012 -1.760 4.839 PANX1
Reduction of cytosolic Ca++ levels 0.009 -1.744 4.794 SRI
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4.5 GENE EXPRESSION ANALYSIS 
 From our breast cancer classification, it was found that accuracy, precision, recall and F-score 
decreased when fusion events from TNBC and ER+ types were combined. As a result, we hypothesized 
the regulation patterns surrounding either of the gene fusion partners’ pathways would be affected.  We 
also hypothesized that this may be a good feature for our gene fusion classification model.  
 To test this hypothesis, we found the Reactome pathway neighbors within a distance of two 
away from either fused gene using PathwayCommons. This takes into account genes directly upstream 
and downstream of the gene on the same pathway. However, this also takes into account genes that are 
direct neighbors of genes that are directly adjacent to the gene fusion partners. This method allows us 
to explore the network surrounding the pathway more efficiently and more closely look at how the gene 
fusion affects gene expression for genes that are not in the same pathway. 
 After the gene neighbors are determined for both cancer and healthy gene fusions, their 
expression values are detected using the Tuxedo Suite. Tophat (Trapnell, 2009) was used to align 
samples to the genome and Cufflinks (Trapnell, 2010; Trapnell, 2013) was used to quantify read counts 
and normalize based on read length. ΔFPKM was detected using the following formula for neighbors 
of healthy and cancer gene fusion events in each cancer studied: 
ΔFPKM = FPKM𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 − FPKM𝑐𝑐𝑛𝑛𝑛𝑛𝑐𝑐𝑐𝑐𝑛𝑛 
 From here the FPKM is converted into a z-score in order to further normalize the samples. 
Standard deviation and mean values are calculated for the healthy samples and then applied to the 
following formula for both cancer and healthy neighbors. For cancer patients, the z-score was 
calculated using the healthy standard deviation and mean, in order to compare the two groups to see 
where the cancer was on the normal curve: 
𝑧𝑧 = 𝑥𝑥 −  𝜇𝜇𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
𝜎𝜎𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
 
 Where z is the z-score, x is the delta FPKM of a particular gene, µ is the mean of the non-
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malignant gene fusion neighbors and σ us the standard deviation of the non-malignant fusion 
neighbors. To find the most differentially expressed of these samples, the genes were filtered so that 
only genes with a z-score of > 3 or < -3 were present and differential expression was measured.  
Differentially expressed neighbors of gene fusion partners were mapped to histograms to study 
the density. From here, we can determine that the density of healthy and cancer gene fusion neighbors 
is the same for each type of cancer, as expected (Figures 13-15).  
We looked at all gene fusions that we associated with cancers and tried to find their overlap in 
their pathway neighbors, determined as mentioned above (Figure 16). Amongst all of the cancers there 
were two genes that were common amongst all of the cancers, B2M and PABPC1. B2M is a gene that 
codes for a serum protein found In the MHC class I heavy chain. It is also known to be associated with 
colon cancer (Kheirelseid, 2010). PABPC1 is a gene which encodes polyadenylate binding protein 1 
which binds the poly-A tail of the mRNA (Grosset, 2000). An interesting finding that might need to be 
studied further is that the expression values for our representative hematological cancer (ALL) has a 
different gene expression pattern for both of these genes than our two representative solid tumor 
cancers (BC, and CRC). B2M  is upregulated in ALL, while downregulated in both solid tumors, and 
PABPC1 is downregulated in ALL, while upregulated in both solid tumors. While we only studied 
three cancers, it might be interesting to look at the differences between other hematological cancers and 
solid tumors. 
Next, we were interested in finding the unique neighbor genes of gene fusion events in each 
respective cancer. We took the set difference between the unique neighbor genes in healthy and the 
unique neighbor genes in cancer. It is hypothesized that the unique gene fusion neighbors will be 
associated with cancer pathways or have functions related to cancer. Since we did not specify whether 
these genes will be up or down regulated (we took both z-scores greater than 3 and less than -3) and the 
genes can come from anywhere, we believe that if these neighbor genes are associated with cancer 
pathways, then these fusion neighbors might be good therapeutic targets. 
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Acute Lymphoblastic Leukemia had only one unique differentially expressed neighbor for its 
cancer (Figure 17) and healthy (Figure 18) gene fusion events. The unique fusion neighbor present in 
Acute Lymphoblastic Leukemia is NPM1. NPM1 is involved in the regulation of the ARF/p53 pathway. 
It is also involved in nucleic acid binding and protein homodimerization, according to its Gene 
Ontology terms. It is known as a frequently mutated gene in hematological cancers (Balusu, 2011). 
This gene is upregulated in our cancer dataset. The unique fusion neighbor present in healthy human 
cord blood is CALR. This gene is a member of the JAK/STAT pathway, which while known for its 
diabetes signaling capabilities, its members have also showed up in cancer pathways. JAK is a tyrosine 
kinase, which members are frequently associated with fusion events and the JAK/STAT pathway is 
commonly affected in cancer. Its role in normal cells is to serve as an “eat-me” sign for phagocytosis 
(Lu, 2014). This gene is downregulated in our cancer dataset. 
For our unique gene fusion pathway neighbors in breast cancer (Figure 19) three genes are 
interesting, GAPDH, MGST1 and ACTA2. GAPDH, despite its use as a housekeeping gene, is actually 
well known to have increased expression in certain types of solid cancers (Tokunaga, 1987). SNPs for 
MGST are found in colorectal cancer. SNPs in this gene could contribute to the risk in young people (< 
50 years old) (Iida, 2001). ACTA2 encodes Alpha smooth muscle actin 2, and studies have shown its 
connection with early brain metastasis of lung adenocarcinoma. For our unique gene fusion pathway 
neighbors in healthy breast tissue (Figure 20), some of the interesting genes that are related with cancer 
are GPX3 and RBP4. GPX3 is a in the glutathione peroxidase family and shown to be downregulated in 
cancer (Zhang, 2010). It is also required for synthesis and storage of intracellular triglycerides. RBP4, 
or Retinol Binding Protein 4, is also involved in the JAK/STAT pathway. RBP4 isoforms have also been 
shown to be decreased in liver cancer (Frey, 2008).  
Finally, for our unique gene fusion pathway neighbors in colorectal cancer (Figure 21), some of 
the interesting genes that are related with cancer include CCT3, HMGA1. CCT3 is a chaperone protein 
and assists with the folding of proteins upon ATP hydrolysis. It is also associated with hepatocellular 
49 
 
carcinoma. HMGA1 is a gene that is associated with tumor progression in TNBC breast cancer cells 
(Shah, 2013). Three genes were found as unique for our gene fusion pathway neighbors in healthy 
colon tissue (Figure 22), GCNT3, SLC44A4 and SRI. Both SLC44A4 and SRI are signaling genes, with 
SLC44A4 being a sodium-dependent transport protein and SRI being a calcium binding protein. GCNT3 
is actually a marker for colon cancer and lower expression indicates higher probability of disease-free 
survival (Gonzalez-Vallinas, 2014). 
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Figure 13: Delta FPKM of acute lymphoblastic leukemia fusion neighbor densities healthy (top) and 
cancer (bottom). 
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Figure 14: Delta FPKM of breast cancer fusion neighbor densities healthy (top) and cancer (bottom). 
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Figure 15: Delta FPKM of colorectal cancer fusion neighbor densities healthy (top) and cancer 
(bottom). 
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Figure 16: Venn diagram of all of the overlapping neighbors between cancer fusion neighbors in ALL 
(blue), breast cancer (pink) and colorectal cancer (green) 
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Figure 17: Relative expression of B2M, which is a common gene fusion neighbor between colon 
cancer, acute lymphoblastic leukemia and breast cancer 
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Figure 18: Relative expression of PABPC1, which is a common gene fusion neighbor between colon 
cancer, acute lymphoblastic leukemia and breast cancer 
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Figure 19: Acute lymphoblastic leukemia unique in cancer fusion neighbors relative gene expression 
values for both cancer (blue) and healthy (orange). 
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Figure 20: Acute lymphoblastic leukemia unique in healthy fusion neighbors relative gene expression 
values for both cancer (blue) and healthy (orange). 
 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
CALRR
el
at
iv
e 
G
en
e 
Ex
pr
es
si
on
 L
ev
el
s
Gene Name
Cancer Healthy
58 
 
 
 
Figure 21: Breast cancer unique in cancer fusion neighbors relative gene expression values for both 
cancer (blue) and healthy (orange). 
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Figure 22: Breast tissue unique in healthy fusion neighbors relative gene expression values for both 
cancer (blue) and healthy (orange). 
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Figure 23: Colorectal cancer unique in cancer fusion neighbors relative gene expression values for 
both cancer (blue) and healthy (orange). 
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Figure 24: Colorectal unique in cancer fusion neighbors relative gene expression values for both 
cancer (blue) and healthy (orange). 
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5. DISCUSSION 
 Since the start of our current age of genomics and next-generation sequencing, new mutations 
are able to be discovered and confirmed more quickly. SNVs and CNVs have been studied in depth 
through large scale GWAS studies and other means, but gene fusion detection and analysis is still 
inconclusive. The deluge of gene fusion detection software programs leaves us with more questions 
than answers at this point, especially because there are over 30 different software programs and most 
have been shown through independent studies as having little overlap. The purpose of our study was 
two-fold: (1) Accurately classify gene fusion events belonging to cancer and healthy tissue or cells and 
(2) characterize the gene fusion pathway landscape and garner better insight into how gene fusions 
might drive cancer. 
 Through this study, we were able to accurately classify gene fusion events derived from 
FusionMap as belonging to the cancer or healthy samples, despite the fact that many overlapping gene 
fusion events between cancer and healthy samples were found. More analyses need to be done in order 
to determine if semi-supervised learning is the best model for gene fusion data, since semi-supervised 
models performed similar to supervised models after performing feature selection. Modifying our 
features to include gene expression information of pathway neighbors may improve our model. Our 
model does solve the problem of determining a tissue-specific model for classifying gene fusion events, 
since we observe that there are no overlapping genes between any of the genes involved in gene fusions 
or their neighbors.  
 Through exploring the gene fusion pathway neighbors we were able to observe many gene 
cancer related pathways affected, as represented by the functions of each of the unique pathway 
neighbor genes of gene fusion events found as having z-scores of greater than 3 or less than -3. Each 
type of tissue, whether the neighbor was unique to cancer or healthy, contained at least one gene that 
was within a cancer pathway. This predicts the existence of the transcription ripple effect caused by 
gene fusions to the rest of their pathway networks. Further research and possible collaboration with a 
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wet lab would be needed to see under which circumstances this holds true. 
 Not all of the gene fusion neighbors found were prevalent in cancer pathways, so it is important 
to further look into the literature to find a connection between these genes and their fusions. This 
includes looking into whether the gene fusions have frame-shift mutations, intact domains or produce a 
functional gene product.   
 Our long-term goal is to represent our pathway neighbor analysis as a feature in our algorithm. 
It is predicted that this will improve our algorithm, as it seems like cancer pathways are overall affected 
in gene fusion events. In order to do this, we would also have to test a normal dataset in order to see if 
there is a significant difference between our findings and non-fused gene neighbors in cancer. We 
would also like to test our current model with an independent healthy sample from another lab, which 
would make sure our model is not biased based on lab.  
 In order to improve our pathway neighbor analysis, we would like to connect the pathway 
neighbors found back to the gene fusion events that they are associated with. Can we find a direct 
connection between these genes and their fused neighbors? Currently, both upstream and downstream 
effects are grouped together. It might be interesting to isolate upstream and downstream effects to 
compare if downstream effects have greater differential expression than upstream effects.  
 Kinases and transcription factors are heavily involved in gene fusion events. It is hypothesized, 
if our gene fusions detected from FusionMap are not false positives, that a significant portion of them 
will contain transcription factors or kinases. It would be useful to count these groups in each of the 
datasets used, and separate into cancer and healthy to observe differences.  
 Overall in this study, we developed a model able to predict fusion events associated with cancer 
and healthy phenotypes with about an 85% accuracy. We have also found that pathway neighbors of 
gene fusion events that are significantly differentially expressed have direct connections to cancer 
pathways. These neighbors could be used to further improve therapeutic targets for cancer, especially 
those cancers known to strongly be affected by gene fusions. 
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